Entering text into the input field will update the search result below

Seagen’s Tukysa wins European approval for breast cancer

Feb. 12, 2021 7:45 AM ETSeagen Inc. (SGEN) StockBy: SA News Team
  • The European Commission (EC) has granted marketing authorization for Seagen's (NASDAQ:SGEN) Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SGEN--
Seagen Inc.